TABLE 1

Demographic Characteristics of Adolescent Girls Enrolled in the Clinical Trial, Overall and by Study Arm

Overall, n (%)aCombined Intervention, n (%)CDS, n (%)Family-Focused Decision Support, n (%)No Intervention, n (%)
N22 4865561555756805688
Raceb
 White, non-Hispanic12 429 (55)3027 (54)3028 (54)3192 (56)3182 (56)
 African American, non-Hispanic6997 (31)1820 (33)1822 (33)1641 (29)1714 (30)
 Asian, non-Hispanic428 (2)110 (2)93 (2)114 (2)111 (2)
 Other2632 (12)604 (11)614 (11)733 (13)681 (12)
Age group
 11–13 y15 544 (69)3898 (70)3885 (70)3885 (68)3876 (68)
 14–17 y6942 (31)1663 (30)1672 (30)1795 (32)1812 (32)
Insurance status
 Private17 903 (80)4554 (82)4546 (82)4392 (77)4411 (78)
 Nonprivate4583 (20)1007 (18)1011 (18)1288 (23)1277 (22)
Center
 Urban resident teaching practices4569 (20)1013 (18)1000 (18)1278 (23)1278 (22)
 Nonteaching practices17 917 (80)4548 (82)4557 (82)4402 (77)4410 (78)
Hormonal Contraceptive Usec
 Yes730 (3)181 (3)180 (3)175 (3)194 (3)
 No21 756 (97)5380 (97)5377 (97)5505 (97)5494 (97)
Vaccine Refusald
 Yes218 (1)58 (1)54 (1)51 (1)55 (1)
 No22 268 (99)5503 (99)5503 (99)5629 (99)5633 (99)
Doses Completed at Time of Randomization
 None17 658 (79)4369 (79)4413 (79)4440 (78)4436 (78)
 1 HPV dose2343 (10)608 (11)564 (10)589 (10)582 (10)
 2 HPV doses2485 (11)584 (10)580 (11)651 (12)670 (12)
  • a No significant differences were observed between study arms (P > .05 for all comparisons).

  • b Race/ethnicity data were collected from the EHR; race/ethnicity is reported by families and recorded by practice staff at each study site.

  • c Hormonal contraceptives were included as a marker for possible sexual initiation, which might increase the likelihood that girls received the HPV vaccine.

  • d Vaccine refusal was measured based on documentation by the clinician in a patient’s problem list, a standard approach at study practices to document families refusing multiple vaccines.